Pharmacotherapy of Paget's disease of bone

Bibliography

• Seitz S, Priemel M, Zustin J, Paget's dsease of bone: histologic analysis of 754 patients. J Bone Miner Res 2009;24:62-9
   PubMed Web of Science ®Google Scholar
• Renier JC, Audran M. Progression in length and width of pagetic lesions, and estimation of age at disease onset. Rev Rhum 1997;64:35-43
   Google Scholar
• Renier JC, Audran M. Polyostotic pagets disease – a search for lesions of different durations and for new lesions. Rev Rhum 1997;64:233-42
   Google Scholar
• Haddaway MJ, Davie MWJ, McCall IW, Effect of age and gender on the number and distribution of sites in Paget's disease of bone. Br J Radiol 2007;80:532-6
   PubMed Web of Science ®Google Scholar
• Naot D, Bava U, Matthews B, Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone. J Bone Miner Res 2007;22:298-309
   PubMed Web of Science ®Google Scholar
• Cundy T, Bolland M. Paget disease of bone. Trends Endocrinol Metab 2008;19:246-53
   PubMedGoogle Scholar
• Hamadouche M, Mathieu M, Topouchian V, Transfer of Paget's disease from one part of the skeleton to another as a result of autogenous bone-grafting – a case report. J Bone Joint Surg Am 2002;84A:2056-61
   Google Scholar
• Kanis JA. Pathophysiology and Treatment of Paget's Disease of Bone. Martin Dunitz; London: 1991
   Google Scholar
• Layfield R, Hocking LJ. SQSTM1 and Paget's disease of bone. Calcif Tissue Int 2004;75:347-57
   PubMedGoogle Scholar
• Rhodes EC, Johnson-Pais TL, Singer FR, Sequestosome 1 (SQSTM1) mutations in Paget's disease of bone from the United States. Calcif Tissue Int 2008;82:271-7
   PubMedGoogle Scholar
• Bolland MJ, Tong PC, Naot D, Delayed development of Paget's disease in offspring inheriting SQSTM1 mutations. J Bone Miner Res 2007;22:411-15
   PubMed Web of Science ®Google Scholar
• Albagha OME, Wani SE, Visconti MR. Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nat Genet 2011;43:685-9
   PubMed Web of Science ®Google Scholar
• Friedrichs WE, Reddy SV, Bruder JM, Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. J Bone Miner Res 2002;17:145-51
   PubMedGoogle Scholar
• Matthews BG, Afzal MA, Minor PD, Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease. J Clin Endocrinol Metab 2008;93:1398-401
   PubMedGoogle Scholar
• Kurihara N, Hiruma Y, Yamana K, Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab 2011;13:23-34
   PubMed Web of Science ®Google Scholar
• Cundy HR, Gamble G, Wattie D, Paget's disease of bone in New Zealand: continued decline in disease severity. Calcif Tissue Int 2004;75:358-64
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Selby P, Leufkens HGM, Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res 2002;17:465-71
   PubMed Web of Science ®Google Scholar
• Wallace E, Wong JC, Reid IR. Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. Arch Int Med 1995;155:1813-15
   PubMedGoogle Scholar
• Eekhoff M, van der Klift M, Kroon HM, Paget's disease of bone in the Netherlands: a population-based radiological and biochemical survey – the Rotterdam Study. J Bone Miner Res 2004;19:566-70
   PubMedGoogle Scholar
• Langston AL, Campbell MK, Fraser WD, Clinical determinants of quality of life in Paget's disease of bone. Calcif Tissue Int 2007;80:1-9
   PubMed Web of Science ®Google Scholar
• Davie M, Davies M, Francis R, Paget's disease of bone: a review of 889 patients. Bone 1999;24:11-12S
   Google Scholar
• Barker DJP. The epidemiology of Paget's disease of bone. Br Med Bull 1984;40:396-400
   PubMedGoogle Scholar
• Altman RD, Bloch DA, Hochberg MC, Prevalence of pelvic Paget's disease of bone in the United States. J Bone Miner Res 2000;15:461-5
   PubMed Web of Science ®Google Scholar
• Bastin S, Bird H, Gamble G, Paget's disease of bone-becoming a rarity? Rheumatology 2009;48:1232-5
   PubMedGoogle Scholar
• Reid IR, Davidson JS, Wattie D, Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 2004;35:224-30
   PubMed Web of Science ®Google Scholar
• Doyle FH, Greenberg PB, Joplin GF, Radiological evidence of a dose-related response to long-term treatment of Paget's disease with human calcitonin. Br J Radiol 1974;47:1-8
   PubMedGoogle Scholar
• Singer FR, Aldred JP, Neer RM, An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 1972;51:2331-8
   PubMed Web of Science ®Google Scholar
• Dunford JE, Thompson K, Coxon FP, Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42
   PubMed Web of Science ®Google Scholar
• Nancollas GH, Tang R, Phipps RJ, Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006;38:617-27
   PubMed Web of Science ®Google Scholar
• Altman RD, Johnston CC, Khairi MR, Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med 1973;289:1379-84
   PubMed Web of Science ®Google Scholar
• Smith R, Russell RGG, Bishop MC, Paget's disease of bone: experience with a diphosphonate (disodium etidronate) in treatment. Q J Med 1973;42:235-56
   PubMedGoogle Scholar
• de Vries HR, Bijvoet OLM. Results of prolonged treatment of Paget's disease of bone with disodiun ethane-1- hydroxy-1, 1-diphosphonate (EHDP). Neth J Med 1974;17:281-98
   PubMedGoogle Scholar
• Khairi MRA, Johnston CC, Altman RD, Treatment of Paget's disease of bone (osteitis deformans). JAMA 1974;28:562-7
   Google Scholar
• Kantrowitz FG, Byrne MH, Schiller AL, Clinical and biochemical effects of diphosphonates in Paget's diseasde of bone. Arthritis Rhem 1975;18:407
   Google Scholar
• Khairi MRA, Altman RD, De Rosa GP, Sodium etidronate in the treatment of Paget's disease of bone: a study of long term results. Ann Intern Med 1977;87:656-63
   PubMedGoogle Scholar
• . FrijlinkWB, te Velde J, Treatment of Paget's disease with (3-amino-1-hydoxypropylidene)-1,1-bisphosphonate (APD). Lancet 1979;i:799-803
   Google Scholar
• Dodd GW, Ibbertson HK, Fraser TRC, Radiological assessment of Paget's disease of bone after treatment with the bisphosphonates EHDP and APD. Br J Radiol 1987;60:849-60
   PubMedGoogle Scholar
• Reid IR, King AR, Alexander CJ, Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988;i:143-6
   Google Scholar
• Reid IR, Nicholson GC, Weinstein RS, Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate – a randomized, placebo-controlled trial. Am J Med 1996;101:341-8
   PubMed Web of Science ®Google Scholar
• Siris E, Weinstein RS, Altman R, Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996;81:961-7
   PubMed Web of Science ®Google Scholar
• Cukier k, Nicholson GC, Long-term follow-up of alendronate treatment in Paget's disease Presented at the International Symposium on Paget's Disease; 8 – 9 July 2009; Oxford, UK
   Google Scholar
• Hosking DJ, Eusebio RA, Chines AA. Pagets-disease of bone – reduction of disease activity with oral risedronate. Bone 1998;22:51-5
   PubMed Web of Science ®Google Scholar
• Singer FR, Clemens TL, Eusebio RA, Risedronate, a highly effective oral agent in the treatment of patients with severe Pagets-disease. J Clin Endocrinol Metab 1998;83:1906-10
   PubMed Web of Science ®Google Scholar
• Siris ES, Chines AA, Altman RD, Risedronate in the treatment of Pagets-disease of bone – an open label, multicenter study. J Bone Miner Res 1998;13:1032-8
   PubMed Web of Science ®Google Scholar
• Miller PD, Brown JP, Siris ES, A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med 1999;106:513-20
   PubMed Web of Science ®Google Scholar
• Reid IR, Miller P, Lyles K, Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005;353:898-908
   PubMed Web of Science ®Google Scholar
• Hosking D, Lyles K, Brown JP, Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 2007;22:142-8
   PubMed Web of Science ®Google Scholar
• Reid IR, Lyles K, Su G, A single infusion of zoledronic acid produces sustained remissions in Paget's disease – data to 6.5 years. J Bone Miner Res 2011;26:2261-2270
   PubMed Web of Science ®Google Scholar
• Cornish J, Bava U, Callon KE, Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. Bone 2011;49:710-16
   PubMedGoogle Scholar
• Heaney RP, Armas LAG, Shary JR, 25-Hydroxylation of vitamin D-3: relation to circulating vitamin D-3 under various input conditions. Am J Clin Nutr 2008;87:1738-42
   PubMed Web of Science ®Google Scholar
• Lyles KW, Colon-Emeric CS, Magaziner JS, Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809
   PubMed Web of Science ®Google Scholar
• Reid IR, Cundy T. Osteonecrosis of the jaw. Skeletal Radiol 2008; published online; doi: 10.1007/s00256-008-0549-x
   PubMedGoogle Scholar
• Kilcoyne A, Heffernan EJ. Atypical proximal femoral fractures in patients with paget disease receiving bisphosphonate therapy. Am J Roentgenol 2011;197:W196-7
   PubMedGoogle Scholar
• Langston AL, Campbell MK, Fraser WD, Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J Bone Miner Res 2009;25:20-31
   Google Scholar
• Black DM, Reid IR, Boonen S, The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial. J Bone Miner Res 2012;27:243-254
   PubMed Web of Science ®Google Scholar
• Reid IR, Miller PD, Brown JP, Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010;25:2256-65
   PubMed Web of Science ®Google Scholar
• Miller PD, Bolognese MA, Lewiecki EM, Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase II clinical trial. Bone 2008;43:222-9
   PubMed Web of Science ®Google Scholar
• Eisman JA, Bone HG, Hosking DJ, Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 2011;26:242-51
   PubMed Web of Science ®Google Scholar
• Lyles KW, Siris ES, Singer FR, A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res 2001;16:1379-87
   PubMed Web of Science ®Google Scholar